PRNewswire -- Angelini Labopharm today announced that OLEPTRO™ (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, is now commercially available in the United States. OLEPTRO™ is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO™ has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone. OLEPTRO™ was approved by the U.S. Food and Drug Administration (FDA) on February 2, 2010. MDD is a common mental illness often characterized by a combination of emotional, somatic, and behavioral symptoms. It affects more than 14 million adults in the U.S. and is the leading cause of disability globally.
